Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$37.60 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)127.28K
Market Cap
HK$1.73B
Enterprise ValueHK$891.69M
Total Cash (Recent Filing)HK$718.20M
Total Debt (Recent Filing)HK$45.91M
Price to Earnings (P/E)17.0
Beta1.49
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.12
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Bulls Say, Bears Say
Bulls Say
Revenue Scale-UpRevenue rose from ~HK$15m in 2020 to ~HK$398m in 2025, evidencing sustained top-line scaling and stronger market penetration. This growth supports fixed-cost absorption, broader distribution and a more durable revenue base that can underpin medium-term profitability if maintained.
High Margins & ProfitabilityMargins inflected sharply to gross ~69%, operating ~11% and net ~20% in 2025, showing strong unit economics and operating leverage. Sustained high gross margins in a medical-device business support reinvestment and cash generation, bolstering long-term profit stability if preserved.
Improved Cash GenerationThe company produced positive operating cash flow (~HK$154m) and free cash flow (~HK$140m) in 2025, indicating improved cash conversion. Strong FCF enhances financial flexibility to fund growth, capex or working capital, supporting durable operations and reduced refinancing dependence.
Bears Say
Durability Of ProfitabilityThe company was loss-making as recently as 2024 and has a history of volatile earnings and cash flows. While 2025 showed a profit turn, recent losses indicate profitability is not yet proven across cycles, raising execution and demand-risk for sustained margins and earnings.
Cash Flow VolatilityOperating and free cash flow were meaningfully negative in prior years before 2025's improvement, highlighting volatile cash conversion. Such variability can constrain reinvestment, elevate refinancing risk in downturns, and makes dependable free-cash-flow generation uncertain over time.
Modest Return Metrics & Reinvestment PressureROE improved to only ~7% in 2025, a modest level given recent profitability. If management must continue to reinvest heavily to sustain growth or regulatory/compliance spend, incremental returns may remain limited, potentially diluting long-term shareholder value absent margin expansion.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$37.60 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$1.73B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Aug 28, 2026 which is in 53 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported HK$0.941 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.941.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$0.941 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.091%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.09%
12-Months-Change
Fundamentals
Return on Equity
7.53%
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―
Options Prices
Currently, No data available
---